Cargando…
T790M突变的非小细胞肺癌研究现状与前景
Targeted therapy with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) is regarded as the main accepted first-line treatment on EGFR mutation in non-small cell lung cancer (NSCLC). Although targeted therapy for the first and two generation of TKIs may lead to longer progression...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973297/ https://www.ncbi.nlm.nih.gov/pubmed/28302223 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.03.09 |
Ejemplares similares
-
非小细胞肺癌T790M基因突变研究进展
Publicado: (2013) -
原发T790M突变非小细胞肺癌研究进展
Publicado: (2019) -
KRAS突变的非小细胞肺癌的研究进展
Publicado: (2018) -
晚期非小细胞肺癌维持治疗的现状与展望
Publicado: (2010) -
非小细胞肺癌ERCC1表达的转化研究现状
Publicado: (2014)